生物时代实验室与诺华公司合作,达成了一项550万加元的协议,以发展与年龄有关的疾病的治疗。 BioAge Labs partners with Novartis for a $550M deal to develop treatments for age-related diseases.

生物时代实验室与诺华公司在多年交易中合作,旨在发现与年龄有关的疾病的新治疗方法。 BioAge Labs has teamed up with Novartis in a multi-year deal aimed at discovering new treatments for age-related diseases. BioAge可能提前收到多达2 000万美元,潜在的里程碑付款总额可能高达5.3亿美元。 BioAge could receive up to $20 million upfront, with potential milestone payments totaling up to $530 million. 合作将利用BioAge的人类寿命数据和Novartis在生物学练习方面的专门知识来确定新的药物目标。 The collaboration will use BioAge's human longevity data and Novartis's expertise in exercise biology to identify new drug targets. 这一伙伴关系是在BioAge的存量上升14%之后建立的。 This partnership follows a rise in BioAge's stock by 14%.